192 related articles for article (PubMed ID: 33774697)
21. [Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].
van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Haanen JBAG; Aarts MJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Koornstra RH; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM
Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040270
[TBL] [Abstract][Full Text] [Related]
22. Metastatic melanoma to lymph nodes in patients with unknown primary sites.
Cormier JN; Xing Y; Feng L; Huang X; Davidson L; Gershenwald JE; Lee JE; Mansfield PF; Ross MI
Cancer; 2006 May; 106(9):2012-20. PubMed ID: 16568458
[TBL] [Abstract][Full Text] [Related]
23. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
25. Melanoma of unknown primary: New perspectives for an old story.
Boussios S; Rassy E; Samartzis E; Moschetta M; Sheriff M; Pérez-Fidalgo JA; Pavlidis N
Crit Rev Oncol Hematol; 2021 Feb; 158():103208. PubMed ID: 33383207
[TBL] [Abstract][Full Text] [Related]
26. Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients.
Crookes TR; Scolyer RA; Lo S; Drummond M; Spillane AJ
Ann Surg Oncol; 2017 May; 24(5):1378-1385. PubMed ID: 28130620
[TBL] [Abstract][Full Text] [Related]
27. Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor.
Heppt MV; Tietze JK; Reinholz M; Rahimi F; Jung A; Kirchner T; Ruzicka T; Flaig MJ; Berking C
Discov Med; 2015 Oct; 20(110):231-7. PubMed ID: 26562476
[TBL] [Abstract][Full Text] [Related]
28. Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results.
Gambichler T; Chatzipantazi M; Schröter U; Stockfleth E; Gedik C
Oncoimmunology; 2019; 8(12):e1677139. PubMed ID: 31741779
[No Abstract] [Full Text] [Related]
29. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
30. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
31. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
32. Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.
De Andrade JP; Wong P; O'Leary MP; Parekh V; Amini A; Schoellhammer HF; Margolin KA; Afkhami M; Melstrom LG
Ann Surg Oncol; 2020 Dec; 27(13):5240-5247. PubMed ID: 32909128
[TBL] [Abstract][Full Text] [Related]
33. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
34. Melanoma with unknown primary: report and analysis of 24 patients.
Clerico R; Bottoni U; Paolino G; Ambrifi M; Corsetti P; Devirgiliis V; Calvieri S
Med Oncol; 2012 Dec; 29(4):2978-84. PubMed ID: 22460835
[TBL] [Abstract][Full Text] [Related]
35. Melanoma without a detectable primary site with metastases to lymph nodes.
Rutkowski P; Nowecki ZI; Dziewirski W; Zdzienicki M; Pieñkowski A; Salamacha M; Michej W; Trepka S; Bylina E; Ruka W
Dermatol Surg; 2010 Jun; 36(6):868-76. PubMed ID: 20482725
[TBL] [Abstract][Full Text] [Related]
36. Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome.
Hughes MC; Wright A; Barbour A; Thomas J; Smithers BM; Green AC; Khosrotehrani K
Int J Cancer; 2013 Dec; 133(12):3000-7. PubMed ID: 23754707
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
39. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
Jochems A; Schouwenburg MG; Leeneman B; Franken MG; van den Eertwegh AJ; Haanen JB; Gelderblom H; Uyl-de Groot CA; Aarts MJ; van den Berkmortel FW; Blokx WA; Cardous-Ubbink MC; Groenewegen G; de Groot JW; Hospers GA; Kapiteijn E; Koornstra RH; Kruit WH; Louwman MW; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MW; van der Hoeven JJ
Eur J Cancer; 2017 Feb; 72():156-165. PubMed ID: 28030784
[TBL] [Abstract][Full Text] [Related]
40. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.
Katz KA; Jonasch E; Hodi FS; Soiffer R; Kwitkiwski K; Sober AJ; Haluska FG
Melanoma Res; 2005 Feb; 15(1):77-82. PubMed ID: 15714125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
